The Tel Aviv, Israel–based company said the integration of the Accipio AI-powered software into Philips’ CT systems will help caregivers identify and prioritize patients suffering from stroke, traumatic brain injury, head trauma and other life-threatening conditions by detecting ICH.
The Accipio ICH and stroke platform is designed to analyze medical imaging data, supporting acute care physicians by identifying patients with suspected intracranial hemorrhage and providing data within minutes while using non-contrast head CT imaging.
Accipio Ix is designed for automatic identification and prioritization of non-contrast head CT images with suspected ICH, while Accipio Ax is designed to provide automatic slice-level annotation of suspected ICH. Both are cleared by the FDA and have CE Mark approval.
MaxQ AI said the Accipio platform will be available with the new Philips CT systems and as an upgrade to previously installed Philips CT systems in both U.S. and European markets in 2020.
“Designed for seamless integration into Philips CT systems and workflow for the caregiver, our AI-powered medical diagnostic platform – coupled with the vast global offerings from Philips – will bring critical minutes-matter decisions directly to wherever the caregiver needs them most,” MaxQ AI CEO Gene Saragnese said in a news release. “Through this powerful collaboration, we will empower physicians to better identify and prioritize patients with a suspected ICH, which have the potential to save lives, improve the quality of care, and lower healthcare costs.”
“We are advancing patient care by co-creating with our customers to bring innovations in CT system design, workflow, radiation dose management, image quality, advanced clinical applications and improved total cost of ownership,” added Karim Boussebaa, Philips’ GM of computed tomography & advanced molecular imaging. “As healthcare continues to transform from a volume- to a value-based approach, and the amount of data available for each clinical decision dramatically grows, the integration of MaxQ’s Accipio AI-powered solutions with our CT systems supports our ambition to achieve the quadruple aim: improved outcomes, enhanced patient experience, increased staff satisfaction, and lowered cost of care delivery.”
In June, MaxQ AI pulled the plug on an initial public offering that was looking to raise approximately $8.1 million, after the IPO was originally filed in August 2018.
Shares of PHG were up 0.1% at $43.25 per share in mid-afternoon trading today.